Biomarker-based management improves outcomes in Crohn’s disease (CD) compared to symptoms alone, but existing biomarkers have limitations. We assessed the diagnostic performance of the Mucosal Healing Index (MHI; PROMETHEUS MonitrTM) for detecting mucosal inflammation in CD.